Orexo partners with ApexB.io and Magellan Rx Management to further research the use of modia, a digital therapeutics tailored for individuals with opioid use disorder.
FREMONT, CA: Orexo, a Swedish pharmaceutical company, collaborates with ApexB.io and Magellan Rx Management to further research the use of modia, a digital therapeutic developed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia, provides individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.
This relationship will offer further data behind the requirement for a seamlessly accessible digital treatment option for OUD. This is a vital time for such a treatment choice as the Centers for Disease Control and Prevention (CDC) called for expanded efforts related to preventing overdose deaths during the pandemic. The US has experienced more than 83,000 deaths due to overdoses – the highest ever recorded in 12 months.
The Covid-19 pandemic has had a profound impact on opioid use in the US, boosting overdose deaths in the last year alone. It is the duty to do everything in our power to bring modia to market rapidly and ahead of schedule so we can help in the effort to save lives. The company is grateful to partner with ApexB.io and Magellan Rx Management, ready to help.
A combination of drug and therapy treatment, or medication-assisted treatment (MAT), is recommended for individuals with OUD. However, only 36 percent of healthcare providers report an adequate number of counselors in their area. With this in mind, modia was tailored to help close the care gap by offering access to quality, evidence-based therapeutic innovations rooted in cognitive behavioral therapy and other effective psychotherapeutic techniques.
Last year, Orexo also boosted the launch of two additional digital therapeutics, deprexis, and vorvida, which address depression and problematic or harmful alcohol use, respectively, in response to raised mental illness Covid-19 pandemic. The first payers have agreed to offer participants the trial, and additional payers are expected to join in the future. A broad launch of modia in the US is forecasting in H2 2021.